14662 results for "PLOS+ONE+Pennsylvania+German+ACS+language+code+pdc+open+access+study"

in 23.53 milliseconds.

• ​Department of Pathology and Tumor Biology, Kyoto University Data Access Committee

  Dac EGAC00001002417

• University of Melbourne Centre for Cancer Research (UMCCR) Data Access Committee

  Dac EGAC00001002442

• Brain Tumour Research Program Telethon Kids Institute Data Access Committee

  Dac EGAC00001002507

• Peter MacCallum Cancer Centre Research Data Access Committee

  Dac EGAC00001002975

• High hyperdiploid acute lymphoblastic leukemia SNP array data Data Access Committee

  Dac EGAC00001003124

• CloneTracer manuscript Data Access Commitee

  Dac EGAC00001003143

• Department of Pathology and Tumor Biology, Kyoto University Data Access Committee

  Dac EGAC00001002159

• Department of Pathology and Tumor Biology, Kyoto University Data Access Committee

  Dac EGAC00001002781

• SEP Mobidic DAC

  Data access committee for U1236 SEP datasets

  Dac EGAC50000000216

• DAC ICARUS LUNG 01

  Data access comittee for ICARUS LUNG 01

  Dac EGAC50000000459

• Data access committee for MS cervical lymph node scRNAseq dataset

  Dac EGAC50000000524

• Data access committee (DAC) for EPI-clone manuscript

  Dac EGAC00001003526

• DAC_ADARIO

  Data access committee for ADARIO / Targeting ADAR1 in Immuno-Oncology

  Dac EGAC50000000343

• BCG prime DNA methylation data

  This dataset contains the DNA methylation data of 384 samples from individuals with one or more comorbidities

  Dataset EGAD00010002767

• Center for Common Disease Genomics (CCDG) - Cardiovascular: eMERGE - Northwestern Cohort

  The National Human Genome Research Institute (NHGRI) has funded the Centers for Common Disease Genomics (CCDG), a collaborative large-scale genome sequencing effort to comprehensively identify rare risk and protective variants contributing to common disease phenotypes and to better understand the general principles of genomic architecture underlying common, complex inherited diseases. This study contains variant calls derived from the whole genome sequence data of an early-onset coronary artery disease case-control cohort selected from the NUgene Project biobank at Northwestern University. Case status was assigned based on the presence of myocardial infarction, coronary artery stenosis greater than 70% in at least one coronary artery, and/or revascularization (coronary angioplasty with or without stent placement or coronary artery bypass grafting) at an early age. In this study "early age" is defined as men 60 years of age or younger and women 70 years of age or younger.

  Study phs001913

• Dysregulation of Alternative Splicing Is a Transcriptomic Feature of Patient Derived Fibroblasts From CAG Repeat Expansion Spinocerebellar Ataxias

  The aim of this study was to characterize transcriptomic changes in patient-derived cell lines of CAG repeat expansion spinocerebellar ataxias (SCAs), using RNA-sequencing (RNA-Seq), to help us better understand disease pathogenesis. The data consists of two SCA1, two SCA3, and one SCA7 cell lines with 5 unaffected controls. Widespread alternative splicing dysregulation was identified across all SCA cell lines. Alternative splicing analysis also revealed that the dysregulation affected disease-relevant pathways with novel skipped-exon splicing events from the RNA-Seq data validated with RT-PCR. These findings are consistent with a previous study that identified robust transcriptomic dysregulation, specifically at the splicing level, in SCA1, -3, and -7 mouse models even at presymptomatic ages. Therefore, alternative splicing has the potential to be used as a biomarker not only in mouse models, but also patient models of repeat expansion SCAs.

  Study phs003759

• Ongoing_mutagenesis_RNAseq

  One of the key questions to be explored is whether the biological processes generating specific mutational signatures continue to operate in the human cancer cell lines or simply reflect past mutagenic activity which is no longer operative. To address this question, we have extracted mutational signatures from 1,000 cancer cell lines of diverse cancer types. Several cell lines with mutational signatures of interest were selected, subcloned over a defined period of time and their genomes sequenced. The increased load of the mutations representative of a specific mutational signature within the genome of a subclone when compared to its parental clone was informative of the on-going mutational processes. To further study the recent observation that some of the clones belonging to a same cell line acquired differencet numbers of mutations over a set period of time, their RNA will be subjected to RNA-sequencing to study their differences.

  Study EGAS00001002364

• Metabolic profiling of patient-derived organoids reveals nucleotide synthesis as a metabolic vulnerability in malignant rhabdoid tumors

  Malignant rhabdoid tumor (MRT) is one of the most aggressive childhood cancers for which no effective treatment options are available. Reprogramming of cellular metabolism is an important hallmark of cancer, with various metabolism-based drugs being approved cancer treatment. In this study, we use patient derived tumor organoids (tumoroids) to map the metabolic landscape of several pediatric cancers. Combining gene expression analyses and metabolite profiling using mass spectrometry, we find nucleotide biosynthesis to be a particular vulnerability of MRT. Treatment of MRT tumoroids with de novo nucleotide synthesis inhibitors lowers nucleotide levels in MRT tumoroids and induces apoptosis. Lastly, we demonstrate invivo efficacy of methotrexate in an MRT PDX mouse model. Our study revealsnucleotide biosynthesis as an MRT-specific metabolic vulnerability, which can ultimately lead to better treatment options for children suffering from this lethal pediatric malignancy.

  Study EGAS00001007877

• Therapeutic Targeting of Ependymoma as Informed by Oncogenic Enhancer Profiling

  Genomic sequencing has driven precision-based oncology therapy; however, genetic drivers remain unknown or non-targetable for many malignancies, demanding alternative approaches to identify therapeutic leads. Ependymomas are chemotherapy-resistant brain tumours, which, despite genomic sequencing, lack effective molecular targets. Here, we mapped active chromatin landscapes in 42 primary ependymomas in two non-overlapping primary ependymoma cohorts. Enhancer regions revealed novel oncogenes, molecular targets, and pathways, which when subjected to small molecule inhibitor or shRNA treatment, increased survival and slowed proliferation in mouse and neurosphere patient-derived models of ependymomas. This study represents one of the largest enhancer mapping study of any cancer type to date, and provides a framework for target and drug discovery for other cancers recalcitrant to therapeutic development because of their lack of known genetic drivers.

  Study EGAS00001002696

• Genetic Analysis of the Chiari I Malformation

  This study used whole exome sequencing (WES) on families affected with Chiari I Malformation (CM1). Individuals were recruited from the Republic of Tartarstan in the Russian Federation, where CM1 has a high prevalence (approximately 413 out of 100,000). At least one-third of these affected individuals have an affected relative. In collaboration with Dr. Enver Bogdanov of Kazan State Medical University, seven extended families affected with CM1 were identified. Eligible participants for this study were required to 1) have CM1 and a family member with syringomyelia or CM1, or 2) be a family member of a patient with CM1 and have at least two immediate family members diagnosed with CM1. Adults and minors were eligible for this study and recruitment was through self and physician referral. Patients were excluded if they had a contraindication to MRI scanning, were unable to understand the risks of testing, were under one year of age, or could not undergo MRI scanning without sedation. Study participants underwent SPGR (Spoiled Gradient Recalled) and T1-weighted MR-imaging of the brain and cervical spinal cord to assess the volume of the posterior fossa, as well as the presence of CM1. Individuals were defined as having CM1 if the inferior aspect of the cerebellar tonsils were lying ≥=2 mm caudal to the foramen magnum. Individuals were defined as having a small posterior fossa volume if the ratio of the posterior fossa volume to the supratentorial volume was < 0.15. Sixty-two patients (both cases and controls) from the seven extended families had DNA extracted from blood lymphocytes contained in 10 milliliters of stored blood. Whole exome sequencing (WES) was performed by the National Intramural Sequencing Center (NISC). These genotype data, as well as the case-control phenotype data on CM1 diagnosis and small posterior fossa diagnosis, were made available to dbGaP.

  Study phs001795

• Walter and Eliza Hall Institute Research Data Access Committee

  Dac EGAC00001002877

• Genetics of gene expression in primary human immune cells Data Access Committee

  Dac EGAC00001003318

• Bolleboom-Gao peri-tumoral snRNA-seq glioblastoma dataset 2022/A - Data Access Committee

  Dac EGAC00001003049

• Genetics of gene expression in primary human immune cells Data Access Committee

  Dac EGAC00001003327

• Data Access Commitee for the project : Methylome profiling of human mesenchymal chondrosarcoma

  Dac EGAC00001003217

• Department of Pathology and Tumor Biology, Kyoto University Data Access Committee

  Dac EGAC00001003220

• Data Access Commitee for single-cell analysis of multiple myeloma and precursors

  Dac EGAC00001002920

• VIB_VRC Data Access Committee

  Dac EGAC00001000042

• Department of Pediatrics, The University of Tokyo, PPB Data Access Committee

  Dac EGAC00001000163

• SA Pathology Data Access Committee

  Dac EGAC00001000220

• The Ingham Institute Gastro-Intestinal Viral Oncology Group Genome Data Access Committee

  Dac EGAC00001000367

• Data Access Committee for COLO829 Somatic reference standard for cancer genome sequencing

  Dac EGAC00001000408

• The Danish Reference Genome - GenomeDenmark data access committee

  Dac EGAC00001000562

• Peter Mac Translational Breast Cancer Genomics and Therapeutics Lab Data Access Committee

  Dac EGAC00001000837

• Data Access Committee for desmoplastic small round cell tumor (DSRCT) RNAseq data.

  Dac EGAC00001000851

• Nagoya University Department of Virology Data Access Committee

  Dac EGAC00001000988

• Stanford Data Access Committee for Multi-Region WES of Metastatic Colorectal Cancer

  Dac EGAC00001001164

• Data Access Commitee of The First Affiliated Hospital of Nanjing Medical University

  Dac EGAC00001001209

• Division of Molecular Oncology, National Cancer Center Research Institute Data Access Committee

  Dac EGAC00001001272

• The Lothian Birth Cohorts Data Access Committee

  Dac EGAC00001001376

• Nicola Murray Centre for Ovarian Cancer Research Data Access Committee

  Dac EGAC00001001588

• The Egyptian Collaborative Cardiac Genomics Project Data Access Committee (ECCO-GEN DAC)

  Dac EGAC00001001594

• The Egyptian Collaborative Cardiac Genomics Project Data Access Committee (ECCO-GEN DAC)

  Dac EGAC00001001680

• VIB CCB Translational Genetics Data Access Commitee

  Dac EGAC00001001808

• Data Access Commitee of the Princess Maxima Center for Pediatric Oncology

  Dac EGAC00001001948

• University of Helsinki Systems Biology and Turku University Hospital Data Access Committee

  Dac EGAC00001001978

• Data access committee for Gut microbiome of BA patients and normal controls

  Dac EGAC00001002146

• Department of Pathology and Tumor Biology, Kyoto University Data Access Committee

  Dac EGAC00001002205

• Division of Molecular Oncology, National Cancer Center Research Institute Data Access Committee

  Dac EGAC00001002331

• NPC genome-wide human SNP array (Hong Kong population) data access commitee

  Dac EGAC00001002581